Gambaran Umum
Axsome Therapeutics, Inc., based in the United States, operates within the pharmaceutical industry, focusing predominantly on the development of novel therapies for central nervous system (CNS) disorders. Key projects include AXS-05, which is under development for multiple CNS conditions including major depressive disorder and Alzheimer’s disease agitation. The company also advances AXS-07, designed for the acute treatment of migraine, and AXS-12, aimed at managing symptoms of narcolepsy. Through a combination of unique molecular approaches and clinical strategies, Axsome seeks to address complex medical needs effectively, enhancing therapeutic benefits and treatment accessibility for patients suffering from serious neurological conditions.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Axsome Therapeutics, Inc. per 2025 Jun 30 adalah 495.03 MM.
- Nilai operating income untuk Axsome Therapeutics, Inc. per 2025 Jun 30 adalah -208.15 MM.
- Nilai net income untuk Axsome Therapeutics, Inc. per 2025 Jun 30 adalah -246.90 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 495.03 | -208.15 | -246.90 |
| 2025-03-31 | 432.16 | -239.22 | -278.27 |
| 2024-12-31 | 385.69 | -252.44 | -287.22 |
| 2024-09-30 | 338.46 | -245.87 | -310.95 |
| 2024-06-30 | 291.49 | -261.94 | -308.55 |
| 2024-03-31 | 251.02 | -245.06 | -296.38 |
| 2023-12-31 | 270.60 | -182.91 | -239.24 |
| 2023-09-30 | 223.44 | -182.46 | -201.83 |
| 2023-06-30 | 182.49 | -162.61 | -184.45 |
| 2023-03-31 | 144.61 | -143.65 | -158.72 |
| 2022-12-31 | 50.04 | -175.40 | -187.13 |
| 2022-09-30 | 25.67 | -153.39 | -159.87 |
| 2022-06-30 | 8.82 | -144.35 | -149.93 |
| 2022-03-31 | -135.15 | -140.78 | |
| 2021-12-31 | -124.71 | -130.40 | |
| 2021-09-30 | -119.79 | -125.59 | |
| 2021-06-30 | -107.51 | -113.63 | |
| 2021-03-31 | -94.44 | -99.68 | |
| 2020-12-31 | -99.09 | -102.90 | |
| 2020-09-30 | -85.63 | -98.54 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Axsome Therapeutics, Inc. pada 2025 Jun 30 adalah -5.06.
- laba per saham yang terdilusi untuk Axsome Therapeutics, Inc. pada 2025 Jun 30 adalah -5.06.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | -5.06 | -5.06 |
| 2025-03-31 | -5.76 | -5.77 |
| 2024-12-31 | -5.99 | |
| 2024-09-30 | -6.53 | -6.53 |
| 2024-06-30 | -6.51 | -6.51 |
| 2024-03-31 | -6.39 | -6.39 |
| 2023-12-31 | -5.27 | |
| 2023-09-30 | -4.54 | -4.54 |
| 2023-06-30 | -4.28 | -4.28 |
| 2023-03-31 | -3.78 | -3.78 |
| 2022-12-31 | -4.60 | |
| 2022-09-30 | -4.08 | -4.08 |
| 2022-06-30 | -3.92 | -3.92 |
| 2022-03-31 | -3.72 | -3.72 |
| 2021-12-31 | -3.47 | -3.47 |
| 2021-09-30 | -3.35 | -3.35 |
| 2021-06-30 | -3.04 | -3.04 |
| 2021-03-31 | -2.67 | -2.67 |
| 2020-12-31 | -2.77 | |
| 2020-09-30 | -2.70 | -2.70 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Axsome Therapeutics, Inc. per 2025 Jun 30 adalah -120.63 MM.
- Nilai cash from investing activities untuk Axsome Therapeutics, Inc. per 2025 Jun 30 adalah -0.47 MM.
- Nilai kas dari aktivitas pendanaan untuk Axsome Therapeutics, Inc. per 2025 Jun 30 adalah 108.46 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -120.63 | -0.47 | 108.46 |
| 2025-03-31 | -118.32 | -0.51 | 88.30 |
| 2024-12-31 | -128.41 | -0.27 | 57.84 |
| 2024-09-30 | -132.57 | -0.25 | 43.59 |
| 2024-06-30 | -167.49 | -0.53 | 46.56 |
| 2024-03-31 | -192.73 | -0.61 | 278.26 |
| 2023-12-31 | -145.08 | -0.58 | 331.01 |
| 2023-09-30 | -142.28 | -0.76 | 332.08 |
| 2023-06-30 | -111.49 | -0.45 | 475.66 |
| 2023-03-31 | -89.68 | -53.56 | 305.05 |
| 2022-12-31 | -116.51 | -53.70 | 284.58 |
| 2022-09-30 | -117.79 | -53.52 | 284.21 |
| 2022-06-30 | -121.81 | -53.71 | 107.70 |
| 2022-03-31 | -113.66 | -0.49 | 34.20 |
| 2021-12-31 | -108.23 | -0.31 | 11.13 |
| 2021-09-30 | -99.94 | -0.33 | 12.53 |
| 2021-06-30 | -88.90 | -0.08 | 39.52 |
| 2021-03-31 | -82.40 | -0.07 | 49.81 |
| 2020-12-31 | -78.46 | -0.05 | 42.41 |
| 2020-09-30 | -75.47 | -0.03 | 234.22 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 |
Efektivitas Manajemen
- roa untuk Axsome Therapeutics, Inc. pada 2025 Jun 30 adalah -0.47.
- roe untuk Axsome Therapeutics, Inc. pada 2025 Jun 30 adalah -0.58.
- roic untuk Axsome Therapeutics, Inc. pada 2025 Jun 30 adalah -0.60.
- croic untuk Axsome Therapeutics, Inc. pada 2025 Jun 30 adalah -0.21.
- ocroic untuk Axsome Therapeutics, Inc. pada 2025 Jun 30 adalah -0.46.
| Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
| 2025-06-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2025-03-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2024-12-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2024-09-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2024-06-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2024-03-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2023-12-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2023-09-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2023-06-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2023-03-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2022-12-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2022-09-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2022-06-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2022-03-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2021-12-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2021-09-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2021-06-30 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2021-03-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2020-12-31 | -0.47 | -0.58 | -0.60 | -0.21 | -0.46 |
| 2020-09-30 | -2.22 | -14.44 | -0.52 | 0.84 | -0.40 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
| Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 |
Pengenal dan Deskriptor
| Kunci Indeks Pusat (CIK) | 1579428 |
Grupong Pang-industriya
| SIC 2834 - Pharmaceutical Preparations |
